Pet Liquid Biopsy Market
Report ID: SQMIG35H2422
Report ID: SQMIG35H2422
sales@skyquestt.com
USA +1 351-333-4748
Report ID:
SQMIG35H2422 |
Region:
Global |
Published Date: February, 2026
Pages:
157
|Tables:
146
|Figures:
78
Global Pet Liquid Biopsy Market size was valued at USD 245.6 Million in 2024 and is poised to grow from USD 283.67 Million in 2025 to USD 898.39 Million by 2033, growing at a CAGR of 15.5% during the forecast period (2026-2033).
The pet liquid biopsy market consists of blood tests that can detect DNA from actively growing tumors and will enable earlier detection, staging, and monitoring of treatment in companion animals. This is important as people increasingly treat pets like family members and want to find the highest level of care and therefore the best opportunity to extend the quality and quantity of their lives. The marketplace for these types of tests began with research in oncology research for humans and has migrated to testing pets with assays that will identify whether or not the animals have tumors.
The ability to conduct this kind of testing using advances in next-generation sequencing and advanced technology has clearly demonstrated to specialty clinics a significant clinical utility of these tests. The technological validation of these tests is the most important factor in driving growth in this market. If the tests are not validated with a high level of analytical sensitivity and specificity, then clinicians will not have a trust relationship with the companies that manufacture these tests.
The driving factor behind the growth of these type of tests was that with the reduction in sequencing prices and increase in cohorts of veterinarians testing on canines and felines that these companies started to validate assays with cohorts of dogs that had already been diagnosed, thus allowing them to prove that they had a method of detecting minimal residual disease. This resulted in oncology centers being able to use these tests for post-surgical monitoring and providing a reliable biomarker platform for pharmaceutical companies conducting clinical trials. As a result, many of these companies have developed partnerships and have created a viable commercial channel to support their products.
How is AI Improving Diagnostic Accuracy in the Pet Liquid Biopsy Market?
In the pet liquid biopsy industry trends, advances in AI improved the accuracy of diagnosing diseases by making low-frequency signals from tumors easier to detect and lowering the amount of biological noise that interferes with detecting the presence of circulating tumor DNA in sample analysis. AI is used to build machine learning models trained on large genomic and clinical datasets for dogs, which help to classify subtle variations in tumor DNA in blood samples and flag cases that require further investigation.
Additionally, through the integration of molecular testing results with cytologic or imaging analyses, veterinarians will be able to get a better understanding of the type of disease present and have their laboratory workflows streamlined so that ambiguous cases are reviewed by experts faster. As a result of these communications, liquid biopsy will become a more viable diagnostic tool in general practice and specialty settings, which will encourage wider adoption and improved care for pets.
Market snapshot - 2026-2033
Global Market Size
USD 245.6 Million
Largest Segment
Consumables
Fastest Growth
Software and Services
Growth Rate
15.5% CAGR
To get more insights on this market click here to Request a Free Sample Report
The global pet liquid biopsy market is segmented into product, circulating biomarkers, technology, application, end use and region. Based on product, the market is segmented into consumables, instruments and software and services. Based on circulating biomarkers, the market is segmented into circulating tumor cells, circulating tumor DNA, Cell-Free DNA, extracellular vesicles and other biomarkers. Based on technology, the market is segmented into multi-gene parallel analysis and single gene analysis.
Based on application, the market is segmented into treatment monitoring, prognosis and recurrence monitoring, treatment selection and diagnosis and screening. Based on end use, the market is segmented into veterinary hospitals, pet clinics, and other end users. Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America, and Middle East & Africa.
As per pet liquid biopsy market forecast, circulating tumor DNA segment dominates because it provides a direct molecular readout of tumor specific mutations and genomic alterations in a minimally invasive format, enabling clinicians to detect actionable changes across diverse cancer types in pets. The high compatibility of circulating tumour DNA assays with sequencing technologies and targeted assays enhances diagnostic confidence. Furthermore, the establishment of translational research and the development of commercial assays will help to stimulate veterinary adoption as they contribute to improved decision making, guiding therapy/chemotherapy changes and as integrated parts of treatment monitoring processes.
As per pet liquid biopsy industry outlook, extracellular vesicles are also rapidly growing in popularity as they contain a variety of biomolecules inside their membranes. Therefore, EVs produce stable RNA and proteomic signals that can be detected through new more efficient methods of isolating and characterizing EVs. Additionally, as the scientific community begins to understand more about the functional role of EVs as potential biomarkers, the pressure to develop commercial assays for EVs will increase, ultimately leading to earlier detection of cancers and better individualized treatment options in veterinary oncology.
As per pet liquid biopsy market analysis, the consumables segment dominates because of dependence on repeat purchases of kits, reagents, and preanalytical materials used in routine testing workflows in veterinary practices to make it easier to adopt new tests through lower capital equipment costs and continuous supply of preserved samples at the different clinics. Reliable assay results are facilitated by having consistent collection and processing consumables which also make it easier for laboratories and clinics to distribute testing products reliably and create consistent revenues which give manufacturers reason to invest in assay validation, distribution partnerships, and training the veterinarian community about new products to increase the clinical use of their products.
However, software and services are the most rapidly expanding area because cloud analytics and bioinformatics streamline interpretation of complex liquid biopsy outputs for clinicians. The availability of reporting via subscription, remote reviewing of the biopsy, and tools that support the decision-making process of a veterinarian has reduced the need for veterinary expertise in the clinic allowing for greater us of genomic testing and the creation of ongoing revenue opportunities associated with continued enhancements to the platforms and the development of care pathways associated with veterinary care.
To get detailed segments analysis, Request a Free Sample Report
There are many aspects of the North America region that provide a strong foundation for the commercialization and clinical validation of liquid biopsy tests in companion animals. There is a large network of veterinary specialty clinics and laboratories that facilitate the fast tracking of liquid biopsy assays through clinical validation and commercialization processes. As well, there are various private investments, significant industry activity with liquid biopsy tests, and numerous collaborations between academia and commercial laboratories that help to develop and improve the technology.
United States Pet Liquid Biopsy Market
As per pet liquid biopsy market outlook, there exists an extensive network of specialty veterinary clinics and laboratories within the United States that is facilitating rapid adoption of liquid biopsy tests in companion animals. Strong collaboration exists between academic institutions and industry partners, whereby many clinical validation and commercialization projects are collaboratively developed.
Canada Pet Liquid Biopsy Market
As per pet liquid biopsy market regional forecast, the market in Canada has a well-established network of veterinary pathology laboratories focused on cancer detection/monitoring for companion animals. The increasing focus on translational research, along with growing collaborative pilot projects in this area, is supporting the clinical integration of liquid biopsy testing into veterinary practices. Other factors promoting the development and continued improvement of liquid biopsy assays and service delivery models include presence of local referral laboratories, veterinarian continuing education programs, and partnerships with international companies that provide liquid biopsy assays to pet owners.
The rapid growth of pet liquid biopsy services in Europe can be attributed to collaborative research efforts, cross-border collaboration, and the growth of local veterinary oncology facilities. The diagnostic manufacturers and reference laboratories have increased their sales activities to meet the growing demand for pet liquid biopsy services in multiple national markets. Professional organizations are promoting standardized practice guidelines to encourage early clinical integration. As clinicians become more familiar with advanced diagnostic tools, pet owners are increasingly engaged in and willing to pursue these services.
Germany Pet Liquid Biopsy Market
The Germany pet liquid biopsy market regional outlook has a solid foundation for diagnostics manufacturing and clinical research that drives the development and validation of rapid tests for companion animals. The existence of reference laboratories, as well as partnerships between industry and academia, contributes to the standardization of the assays.
United Kingdom Pet Liquid Biopsy Market
The UK pet liquid biopsy market growth is characterized by the dynamic adoption of pet liquid biopsy services through private practice and the innovation-oriented ecosystem supporting the rapid adoption of companion animal diagnostics. The strong relationships between biotechnology companies, veterinary clinics, and universities promote pilot studies and commercialization. Investments from both venture capitalists and early adopters support the growth of the pet liquid biopsy market. Flexible service delivery models and educational programmed help integrate pet liquid biopsy testing into the clinical workflow.
France Pet Liquid Biopsy Market
As per pet liquid biopsy industry analysis, France market is evolving through targeted pilot initiatives and the extension of regional diagnostic labs traditionally developed for companion animals that implement sophisticated assays. Increased collaboration between veterinary hospitals and academic research provides pathways for clinical validation and clinician education. There is also an increase in demand for specialty clinicians and commercial entities, leading to an environment conducive to the expansion of services. The outcome of the pilots and the development of networks of collaboration will provide a roadmap for increased clinical integration and improvement of testing services.
Through targeted growth investments in veterinary diagnostics, localized assay creation, and building strategic partner networks with worldwide manufacturers, the Asia Pacific region is building the industry’s foundation. Consequently, regional sources of excellence and referencing labs are developing primary locations for the local patient population for clinical validation and adaptation of liquid biopsy technologies.
Japan Pet Liquid Biopsy Market
The pet liquid biopsy market share for Japan has the advantage of having developed both diagnostic expertise and effective life science infrastructures for the development of local laboratories and assay development specific to companion animals. The collaboration between university research centers and commercial developers facilitates clinical validation and ongoing improvement of these technologies. Also, the presence of veterinary specialists with networks and education that target practitioners assures clinical acceptance of liquid biopsy technologies. Finally, urban demand and effective distribution models and sales channels help convert research innovations into routine diagnostic alternatives for Animal Health providers.
South Korea Pet Liquid Biopsy Market
The pet liquid biopsy market trends in South Korea are moving forward via strong collaboration of biotechnology capabilities with veterinary clinical networks to custom design molecular diagnostics for companion animals. Both types of companies are collaborating to create successful rollouts of clinical assessments and service delivery models. By emphasizing automation in combination with streamlined laboratory processes, clinics have improved the scalability of their practices. Allowing time for training of specialists and developing commercialization practices, will ensure that the acceptance and availability of liquid biopsy technologies are familiar to the veterinarian community within urban and specialty practice environments.
To know more about the market opportunities by region and country, click here to
Buy The Complete Report
Growing Demand for Early Detection
Advances In Noninvasive Technologies
Limited Insurance and Reimbursement Coverage
Limited Clinical Validation and Standardization
Request Free Customization of this report to help us to meet your business objectives.
The competitive environment defined by both large and small participants that either offer products to the veterinary industry or are working on entering the market is evolving rapidly. Both established players in animal health and innovative technology-focused startups are currently executing concrete strategies inclusive of new product launches, clinic purchase partnerships, and targeted acquisitions of distribution channels to get into the veterinary sector.
At Home Testing Expansion
AI Driven Biomarker Innovation
SkyQuest’s ABIRAW (Advanced Business Intelligence, Research & Analysis Wing) is our Business Information Services team that Collects, Collates, Correlates, and Analyses the Data collected by means of Primary Exploratory Research backed by robust Secondary Desk research.
As per SkyQuest analysis, a key driver is growing demand for noninvasive early cancer detection among pet owners seeking advanced care, and a second driver is rapid advances in sequencing, AI and biomarker technologies that improve sensitivity and clinical utility. A restraint is limited insurance and reimbursement coupled with uneven clinical validation and standardization that slows routine adoption. The dominating region is North America due to robust veterinary infrastructure and investment, and the dominating segment is circulating tumor DNA assays which currently lead adoption because they deliver direct molecular readouts and integrate readily with existing sequencing platforms. Overall, the market shows strong growth potential but needs clearer reimbursement and standardization.
| Report Metric | Details |
|---|---|
| Market size value in 2024 | USD 245.6 Million |
| Market size value in 2033 | USD 898.39 Million |
| Growth Rate | 15.5% |
| Base year | 2024 |
| Forecast period | 2026-2033 |
| Forecast Unit (Value) | USD Million |
| Segments covered |
|
| Regions covered | North America (US, Canada), Europe (Germany, France, United Kingdom, Italy, Spain, Rest of Europe), Asia Pacific (China, India, Japan, Rest of Asia-Pacific), Latin America (Brazil, Rest of Latin America), Middle East & Africa (South Africa, GCC Countries, Rest of MEA) |
| Companies covered |
|
| Customization scope | Free report customization with purchase. Customization includes:-
|
To get a free trial access to our platform which is a one stop solution for all your data requirements for quicker decision making. This platform allows you to compare markets, competitors who are prominent in the market, and mega trends that are influencing the dynamics in the market. Also, get access to detailed SkyQuest exclusive matrix.
Table Of Content
Executive Summary
Market overview
Parent Market Analysis
Market overview
Market size
KEY MARKET INSIGHTS
COVID IMPACT
MARKET DYNAMICS & OUTLOOK
Market Size by Region
KEY COMPANY PROFILES
Methodology
For the Pet Liquid Biopsy Market, our research methodology involved a mixture of primary and secondary data sources. Key steps involved in the research process are listed below:
1. Information Procurement: This stage involved the procurement of Market data or related information via primary and secondary sources. The various secondary sources used included various company websites, annual reports, trade databases, and paid databases such as Hoover's, Bloomberg Business, Factiva, and Avention. Our team did 45 primary interactions Globally which included several stakeholders such as manufacturers, customers, key opinion leaders, etc. Overall, information procurement was one of the most extensive stages in our research process.
2. Information Analysis: This step involved triangulation of data through bottom-up and top-down approaches to estimate and validate the total size and future estimate of the Pet Liquid Biopsy Market.
3. Report Formulation: The final step entailed the placement of data points in appropriate Market spaces in an attempt to deduce viable conclusions.
4. Validation & Publishing: Validation is the most important step in the process. Validation & re-validation via an intricately designed process helped us finalize data points to be used for final calculations. The final Market estimates and forecasts were then aligned and sent to our panel of industry experts for validation of data. Once the validation was done the report was sent to our Quality Assurance team to ensure adherence to style guides, consistency & design.
Analyst Support
Customization Options
With the given market data, our dedicated team of analysts can offer you the following customization options are available for the Pet Liquid Biopsy Market:
Product Analysis: Product matrix, which offers a detailed comparison of the product portfolio of companies.
Regional Analysis: Further analysis of the Pet Liquid Biopsy Market for additional countries.
Competitive Analysis: Detailed analysis and profiling of additional Market players & comparative analysis of competitive products.
Go to Market Strategy: Find the high-growth channels to invest your marketing efforts and increase your customer base.
Innovation Mapping: Identify racial solutions and innovation, connected to deep ecosystems of innovators, start-ups, academics, and strategic partners.
Category Intelligence: Customized intelligence that is relevant to their supply Markets will enable them to make smarter sourcing decisions and improve their category management.
Public Company Transcript Analysis: To improve the investment performance by generating new alpha and making better-informed decisions.
Social Media Listening: To analyze the conversations and trends happening not just around your brand, but around your industry as a whole, and use those insights to make better Marketing decisions.
REQUEST FOR SAMPLE
REQUEST FREE CUSTOMIZATION
Global Pet Liquid Biopsy Market size was valued at USD 245.6 Million in 2024 and is poised to grow from USD 283.67 Million in 2025 to USD 898.39 Million by 2033, growing at a CAGR of 15.5% during the forecast period (2026-2033).
Fidoforce, Vidium Animal Health, Illumina, Thermo Fisher Scientific, Heska Corporation, PetDx, QIAGEN, Volition, Freenome Holdings, Vethos, Embark Veterinary, One Health, Ellie Diagnostics, TGen, MiDOG, Basepaws, Antech Diagnostics, Pet-X, AnimalBiome, Exact Sciences Corporation
The key driver of the Pet Liquid Biopsy Market is the growing demand for non-invasive, early cancer detection and disease monitoring in companion animals. Rising awareness of pet health, increasing prevalence of cancer in pets, and the adoption of advanced veterinary diagnostic technologies are significantly fueling market growth globally.
A key trend in the Pet Liquid Biopsy Market is the adoption of next-generation, non-invasive liquid biopsy technologies integrated with molecular diagnostics and AI-driven analytics. These innovations enable earlier detection of cancer and other diseases in pets, improve diagnostic accuracy, and support personalized treatment plans, driving wider adoption among veterinary clinics and research facilities.
North America accounted for the largest share in the Pet Liquid Biopsy Market, driven by advanced veterinary healthcare infrastructure, high adoption of innovative diagnostic technologies, rising prevalence of cancer in companion animals, and strong presence of key market players in the United States and Canada.
Want to customize this report? This report can be personalized according to your needs. Our analysts and industry experts will work directly with you to understand your requirements and provide you with customized data in a short amount of time. We offer $1000 worth of FREE customization at the time of purchase.
Feedback From Our Clients
USA (+1) 351-333-4748
